Asher Bio 将在 AASLD 2022 上展示 AB359 的首个临床前数据，其针对

StephenW

Asher Bio 将在 AASLD 2022 上展示 AB359 的首个临床前数据，其针对 CD8 的 IL-2 乙型肝炎免疫疗法

显示 CD8+ T 细胞靶向免疫疗法治疗慢性病毒感染的潜力
东部夏令时间 2022 年 10 月 21 日上午 9:00

加利福尼亚州南旧金山--(BUSINESS WIRE)--(美国商业资讯)--Asher Biotherapeutics, Inc. (Asher Bio) 今天宣布，该公司是一家专注于开发能够精确利用特定免疫细胞对抗癌症、慢性病毒感染和自身免疫性疾病的疗法的生物技术公司它将在美国肝病研究协会 (AASLD) 2022 年年会上展示 AB359 的首个临床前数据，该药物是其 CD8 靶向白细胞介素 2 (IL-2) 免疫疗法，用于治疗慢性病毒感染，正在于 2022 年 11 月 4 日至 8 日在华盛顿特区举行。临床前数据表明，CD8+ T 细胞中 IL-2 通路的选择性激活可驱动乙型肝炎病毒 (HBV) 模型中的抗病毒活性，并支持 AB359 的开发作为一种潜在的更耐受和更积极的基于 IL-2 的治疗慢性 HBV。

海报展示详情如下：

标题：CD8+ T 细胞中 IL-2 通路的选择性激活驱动乙型肝炎病毒 (HBV) 模型中的抗病毒活性
会议日期和时间：2022 年 11 月 4 日，下午 12:00-1:00外星人
地点：海报厅
摘要编号：1198

关于阿舍生物

Asher Bio 是一家生物技术公司，专注于开发疗法，以精确地利用特定的免疫细胞来对抗癌症、慢性病毒感染和自身免疫性疾病。我们利用我们专有的顺式靶向平台开发疗法，通过选择性激活具有经过验证的抗病功能的特定免疫细胞类型来克服其他基于免疫的治疗的局限性。我们的候选者具有与修饰的免疫调节蛋白（例如细胞因子）相关的抗体。我们的候选设计旨在使我们的候选者能够选择性地激活所需的免疫细胞，而不是其他导致毒性或免疫抑制的细胞。 Asher Bio 由 Ivana Djuretic 和 Andy Yeung 在 Third Rock Ventures 的支持下创立，位于旧金山南部。欲了解更多信息，请访问 www.asherbio.com 并在 Twitter @AsherBio 和 LinkedIn 上关注我们。
联系人

媒体联络
凯瑟琳·莫里斯，耶茨网络
914-204-6412
[email protected]

StephenW

Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections
October 21, 2022 09:00 AM Eastern Daylight Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, its CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections, at the American Association for the Study of Liver Disease (AASLD) 2022 Annual Meeting, being held in Washington, DC, on November 4-8, 2022. The preclinical data indicates that selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a model of hepatitis B virus (HBV) and supports the development of AB359 as a potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.

Details of the poster presentation are as follows:

Title: Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a hepatitis B virus (HBV) model
Session Date and Time: November 4, 2022, 12:00-1:00 p.m. ET
Location: Poster Hall
Abstract Number: 1198

About Asher Bio

Asher Bio is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.
Contacts

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
[email protected]